Alvotech launches first biosimilar of J&J’s Stelara in Europe

by
Contributor since / Followers
5 months ago
Biosimilars pharmaceutical drug bottle on blue background. A safe biological drug that work like biologic medicine. 3d illustration.

Carl Lokko

  • Alvotech (NASDAQ:ALVO) and STADA have launched the first biosimilar of Johnson & Johnson’s (NYSE:JNJ) IL-12 and IL-23 antagonist Stelara, known as Uzpruvo.
  • Uzpruvo is indicated for Crohn’s disease and psoriatic arthritis in adults, and plaque psoriasis in adults and children aged from
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *